License to kill: development of killer T cells observable

November 22, 1999

New model could show how immune system is thwarted by HIV and cancer

BOSTON-November 22, 1999-Researchers at the Center for Blood Research and Harvard Medical School report in the November 23 Proceedings of the National Academy of Sciences the development of an animal model that literally illuminates one of the most dramatic and, until now, obscure events in the body: how the immune system turns immature T cells into specialized killer, or cytotoxic, T cells, capable of seeking out and destroying cells maimed by cancer and infection.

"Now, we have a model that makes it possible to look at a unique and important subset of cells; first to identify it and then analyze it in novel ways," says Ulrich von Andrian, MD, PhD, HMS associate professor of pathology. "This system might allow us to get a better understanding of what provides the T cells' license to kill," he says. Ultimately, the model could be used to clarify such diseases as cancer and AIDS. Some researchers have suspected that viruses and tumor cells may thwart the immune system by taking away T cells' license to kill-that is, by sabotaging the cellular machinery that enables them to attack unwanted cells.

"During the initial stages of an HIV infection, there are lots of cytotoxic T cells in the body but, for some reason, they are not able to contain the infection," says N. Manjunath, PhD, research fellow, and lead author of the study. "Is there a defect in these cells? Understanding normal differentiation with our new model, we might help answer this question."

One of the biggest obstacles to understanding this crucial transformation has been spotting members of this elite corps in large enough numbers to study them. Relatively rare-white blood cells in general number about one in one thousand cells in the bloodstream-T cells also move with the same velocity as other cells in the blood so they tend to get lost in the crush.

To flush them out, von Andrian, Manjunath, and their colleagues created a mouse in which immature T cells were equipped, by genetic means, with a green fluorescent tag. Normally, immature, or naive, T cells learn to identify bits of foreign invaders, called antigens, early on, but develop into fully effective killer T cells-complete with the cellular machinery to kill-only when they encounter actual infection. To coax the quiescent killer T cells into their fully effective state, the researchers infected the mice with a virus. Upon reaching full maturity, almost all of the cells lost their green tag-essentially revealing themselves by becoming invisible.

Why the green light goes out in the mature T cells is not clear but it could be a by-product of other changes occurring inside the differentiating T cells-perhaps the removal of factors that help to drive green fluorescent protein expression. Some or all of these factors may control other genes which need to be turned off in order for the killer T cell to differentiate. Identifying these factors and the genes they control will be "a milestone forward towards understanding how killer T cells develop," says Manjunath.
-end-


Harvard Medical School

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.